Heart failure & cardiomyopathies
Balancing Clinical and Ethical Considerations Related to Placebo Use in Trials of Incretin-Based Therapies in Heart Failure
Study context
- Population
- Future trials of incretin-based therapies (GLP-1 RAs, dual GIP/GLP-1 RAs) in heart failure (HF)
- Comparison
- Placebo-controlled vs active-comparator designs in future incretin-based therapy trials in HF
- Outcome
- Design considerations for placebo use in incretin-based therapy trials in HF
Main finding
As reported in the abstract
- Placebo ensures methodologic rigor but may raise ethical concerns given cardiometabolic benefit with GLP-1 RAs
- Abandoning placebo risks incomplete safety and efficacy data and premature therapeutic extrapolation
- Structured framework proposed: when placebo remains appropriate, when active comparison may be required, and how trial design features can address ethical and operational challenges
Original publication
Balancing Clinical and Ethical Considerations Related to Placebo Use in Trials of Incretin-Based Therapies in Heart Failure. J Am Coll Cardiol. Published 21 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →